The largest database of trusted experimental protocols

Recombinant follicle stimulating hormone

Manufactured by Merck Group
Sourced in Switzerland, Germany

Recombinant follicle stimulating hormone is a lab equipment product that is used to measure and analyze follicle stimulating hormone levels in biological samples. It is a synthetic version of the natural human hormone and is used for research and diagnostic purposes.

Automatically generated - may contain errors

4 protocols using recombinant follicle stimulating hormone

1

Ovarian Cell Survival and Transplantation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The right ovaries (n=114) were individually cultured on inserts (Millicell-CM, 0.4-µm
pore size, Millipore Corp, Billerica, MA, US) at 37˚C and 5% CO2 for 24 hours
in the presence (n=57) and absence (n=57) of LPA. The culture media consisted of 300 µl
α-MEM medium supplemented with 5% foetal bovine serum; 1% insulin, transferrin, and
selenium (Invitrogen, UK), and 100 mIU/ml recombinant follicle stimulating hormone
(Serono, Switzerland). The treated group had 20 µM LPA (INstruchemie, The Netherlands)
added to the culture medium (31 (link)).
The cultured ovaries were observed under an inverted
microscope and some of the cultured ovaries were
considered for assessment of ovarian cell survival using
Calcein AM (n=6 for the LPA-treated group and n=6 for
the non-treated group) and for morphological analysis
with haematoxyline and eosin (n=5 for the LPA-treated
group and n=5 for the non-treated group). The other
cultured ovaries were encapsulated with sodium alginate
and then transplanted under kidney capsule (n=45 for the
LPA-treated group and n=45 for the non-treated group).
+ Open protocol
+ Expand
2

Controlled Ovarian Hyperstimulation Protocol for IVF

Check if the same lab product or an alternative is used in the 5 most similar protocols
Controlled ovarian hyper-stimulation was performed using a short-acting GnRH agonist long protocol. Recombinant follicle-stimulating hormone (Merck Serono) was started at least 14 days after the downregulation of GnRH agonist for complete suppression of estradiol from 75 to 300IU/d. Ovulation was induced with human chorionic gonadotropin, and approximately 36 hours later, oocyte retrieval was performed under transvaginal ultrasonographic guidance. Fertilization was carried out using the standard IVF technique; if male infertility or fertilization failure occurred, oocytes were inseminated by ICSI. Embryo transfer was mostly performed using cleaving stage embryos (day 3). If a patient was at risk of ovarian hyperstimulation syndrome, the embryo was vitrified and transferred to a subsequent substituted cycle.
+ Open protocol
+ Expand
3

In vitro Follicle Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Scaffolds with follicles were cultured in a 24-well plate containing 500 μl αMEM supplemented with 10 mIU ml− 1 recombinant follicle stimulating hormone (Merck; Darmstadt, Germany) 3 mg ml− 1 bovine serum albumin (BSA; Sigma-Aldrich), 5 mg ml− 1 insulin, 5 mg ml− 1 transferrin, and 5 mg ml− 1 selenium (Gibco, UK) for 7 days.
+ Open protocol
+ Expand
4

IVF Protocol with Detailed Procedures

Check if the same lab product or an alternative is used in the 5 most similar protocols
The woman received stimulation treatment with recombinant follicle-stimulating hormone (Merck KGaA), human menopausal gonadotropins (Livzon Pharmaceutical Group Inc.), and gonadotropin-releasing hormone antagonist (Merck KGaA). Transvaginal sonography-guided follicular puncture was performed 36 h after human chorionic gonadotropin (hCG) injection (Livzon Pharmaceutical Group Inc.) injection. The harvested oocytes were denudated enzymatically with recombinant human hyaluronidase and mechanically by pipetting with glass pipettes. The retrieved available spermatozoa were injected into MII oocytes according to a previous description.18 (link) Fertilized embryos were cultured in G1 plus medium (Vitrolife AB, Gothenburg, Sweden) at 37°C in 6% CO2, 5% O2, and 89% N2. Embryo transfer was performed on day 3.
Biochemical pregnancy was confirmed by a positive β-hCG level in the blood or urine 2 weeks after embryo transfer. Ultrasonography was performed at 6-week gestation to confirm the fetal viability. Clinical pregnancy was defined as the presence of a gestational sac in the uterine cavity detected by ultrasound at 4–6 weeks after transfer.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!